Depression as an Immunometabolic Disorder: Exploring Shared Pharmacotherapeutics with Cardiovascular Disease

Mervin Chávez-Castillo¹², Manuel Nava², Ángel Ortega², Milagros Rojas², Victoria Núñez², Juan Salazar²*¹, Valmore Bermúdez³ and Joselyn Rojas-Quintero⁴

¹Psychiatric Hospital of Maracaibo, Maracaibo, Venezuela; ²Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo, Venezuela; ³Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla, Colombia; ⁴Pulmonary and Critical Care Medicine Department, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Abstract: Modern times have seen depression and cardiovascular disease (CVD) become notorious public health concerns, corresponding to alarming proportions of morbidity, mortality, decreased quality of life, and economic costs. Expanding comprehension of the pathogenesis of depression as an immunometabolic disorder has identified numerous pathophysiologic phenomena in common with CVD, including chronic inflammation, insulin resistance, and oxidative stress. These shared components could be exploited to offer improved alternatives in the joint management of these conditions. Abundant preclinical and clinical data on the impact of established treatments for CVD in the management of depression have allowed for potential candidates to be proposed for the joint management of depression and CVD as immunometabolic disorders. However, a large proportion of the clinical investigation currently available exhibits marked methodological flaws which preclude the formulation of concrete recommendations in many cases. This situation may be a reflection of pervasive problems present in clinical research in psychiatry, especially pertaining to study homogeneity. Therefore, further high-quality research is essential in the future in this regard.

Keywords: Depression, cardiovascular disease, chronic inflammation, insulin resistance, oxidative stress, metabolism.

1. INTRODUCTION

In recent years, depression has become one of the most prominent conditions in daily clinical practice and is currently recognized as the leading cause of disability globally, amounting to extremely high direct and indirect financial costs, as well as representing a severe detriment to the quality of life [1]. Interestingly, depression stands alongside cardiovascular disease (CVD) as some of the most prominent problems in public health at present, with CVD being the first cause of mortality and morbidity worldwide [2]. The parallels in the epidemiology of these conditions have sparked abundant research on their interrelated pathophysiology and clinical management.

Although depression is notorious for frequently co-occurring with a myriad of medical comorbidities [3], the link with CVD appears to be particularly powerful, with these entities sharing various risk factors such as chronic stress, physical inactivity, westernized dietary patterns and various metabolic alterations [4] and depression increasing CVD-related mortality by up to 60% [5]. Moreover, they share several pathophysiologic components, including chronic low-grade inflammation, insulin resistance (IR), and dysthrombogenesis [6]. The presence of these shared elements blurs the traditional distinction between mental and physical illness, and could significantly change the management standards of depression and CVD by posing the question: How can the treatment of these conditions be integrated on the basis of their common pathophysiologic components? This review aims to summarize current views on depression as an immunometabolic disorder and its link with CVD, as well as potential novel pharmacological options for their joint management. A literature search was performed on PubMed, EMBASE, Scopus, ISI Web of Science, and Google Scholar databases, from inception to January 2020.

2. REVISITING DEPRESSION AS AN IMMUNOMETABOLIC DISORDER

2.1. From the Sparks to the Flame: Emphasis on Chronic Inflammation

Depression was historically conceived as an illness limited to the brain-mind. However, in recent decades, accumulating evidence has propelled a paradigm shift, where depression is now understood as a systemic disease, with the
Depression as an Immunometabolic Disorder

Current Neuropharmacology, 2020, Vol. 18, No. 11 1139

brain-mind and the body sharing a bidirectional relationship [7]. Chronic inflammation (CI) has been identified as a key component in depression and multiple medical conditions, including CVD, endocrine-metabolic disorders, autoimmune disorders, cancer, and many others [8-11]. Although inflammation is a key physiologic mechanism that aims to preserve homeostasis in the face of injury, it comes at the cost of profound disturbances in the functionality of target tissues [12]. Classic examples of these include vascular changes to allow exudate formation, such as increased endothelial adhesiveness and permeability in response to cytokine signaling [13]. Nonetheless, all tissues are vulnerable to inflammation-induced changes, with each displaying distinct patterns of dysfunction. Thus, systemic CI entails the dysregulation of multiple organ systems [14].

The term “neuroinflammation” has been coined to describe CI in the central nervous system (CNS), which involves activation of microglia, astrocytes and oligodendrocytes, with the release of cytokines, chemokines, acute-phase reactants, and other mediators [15]. Although neuroinflammation may be beneficial in the acute setting, for example, in the limitation of CNS infections; its persistence results in hyperactivation of microglia and neurotoxicity [16, 17]. As with all forms of CI, it is hypothesized to stem from the conflation of extrinsic and intrinsic proinflammatory factors (Fig. 1) [18, 19].

A great body of research has documented the presence of elevated circulating biomarkers of inflammation in participants with depression, including IL-1β, IL-6, IFNγ, TNFα and acute-phase reactants, especially high-sensitivity C-Reactive Protein (hs-CRP), among others [20, 21]. Neuroinflammation and chronic stress are both powerful inducers of the neuroendocrine changes typical of depression, especially sustained activation of sympathetic autonomous signaling and the hypothalamus-pituitary-adrenal axis (HPAA) [22]. Notably, in non-depressed participants, acute and chronic stress, as well as increased inflammatory biomarkers have been associated with “sickness behavior”, which features many depressive characteristics, such as low mood, anhedonia, fatigue, and feeding and sleep disorders [18,23]. Indeed, neuroinflammation can significantly disrupt the metabolism and signaling of monoamines serotonin, norepinephrine and dopamine the central neurotransmitters involved in the neurobiology of depression [24].

Fig. (1). Intrinsic and extrinsic etiologic factors of neuroinflammation. The additive and synergic effects of various intrinsic and extrinsic factors results in chronic inflammation. Neuroinflammation in particular is associated with depression and other neuropsychiatric disorders. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
At the molecular level, oxidative stress (OS), alterations in intraneuronal signaling, disruptions in monoamine metabolism and excitotoxicity are the major pathophysiologic phenomena induced by CI in the context of depression (Fig. 2). Oxidation of inflammatory mediators such as arachidonic acid and its precursor, linoleic acid, entails increased production of reactive oxygen species (ROS) [25-27], which can cause membrane lipid peroxidation, DNA damage and protein carboxylation in neurons [28]. Patients with depression may be especially vulnerable to OS, with lower levels of antioxidant molecules such as glutathione, coenzyme Q10, and possibly zinc, vitamin A and vitamin D; as well as decreased expression of superoxide dismutase and glutathione peroxidase [29, 30]. CI also involves hyperactivity of inducible nitric oxide synthase (iNOS) with increased production of nitric oxide and nitrosative stress (NS) by nitrosylation of proteins, membrane lipids and DNA [29, 31].

Proinflammatory cytokines, OS and NS act as alarm signals and can activate cellular stress-related kinases such as JNK, p38 and IKK-kinase. These promote the nuclear translocation of NF-κB, a potent proinflammatory transcription factor, thus worsening CI in a positive feedback loop [32-34]. Furthermore, patients with depression have been described to exhibit significantly higher levels of IgM antibo-
ies against neoepitopes produced from CI, OS and NS [35]. Neuronal stress also potentiates signaling of the ERK/CREB/Bcl-2 pathway, which promotes apoptosis, alterations in intracellular calcium traffic, and release of cytochrome C [36-38]. Neurons in the prefrontal cortex, anterior cingulate cortex, amygdala and hippocampus may be particularly susceptible to these changes in depression [38-42]. Guan et al. reported prenatally stressed offspring rats to display the decreased expression of these proteins in the prefrontal cortex and hippocampus, in association with depression-like behavior [38]. Conversely, patients with depression may have impaired activity of Nrf-2, a transcription factor that promotes the expression of cytoprotective enzymes such as thioredoxin reductase, glutathione peroxidase, glutathione-S-transferase, haeme oxygenases, and others [43-45]. Indeed, imaging and postmortem studies have identified neuronal and glial modifications, as well as volumetric changes in the hippocampus, amygdala, basal nuclei, the prefrontal cortex, and the anterior cingulate cortex, in association with cognitive impairment [46-48]. This structural neurodegeneration is thought to be due to decreased signaling by neuroprotective mediators, such as the brain-derived neurotrophic factor (BDNF) and fibroblast growth factor (FGF) [49-51]; which in turn are disrupted by the damaging environment promoted by CI and OS [52-54]. These alterations in neurotrophic signaling may be reversible by antidepressant treatment [55, 56]; and BDNF levels have been observed to rise in parallel with the improvement of depressive symptoms in a clinical study by Piccinni et al. [57].

Finally, in neurons, IFN-α, IFN-γ and TNF-α can activate indoleamine 2,3-dioxygenase (IDO), which synthesizes kynurenine (KYN) from tryptophan, the precursor to serotonin, thus implicating decreased production of this monoamine. In addition, the metabolism of kynurenine yields quinolinic acid and kynurenic acid (KA), both of which promote excitotoxicity by binding to NMDA receptors and promoting glutamate release in glial cells [58]. Furthermore, KA may impair dopamine release [59,60]. In patients with hepatitis C undergoing therapy with IFN-α for 24 weeks, this treatment was associated not only with increased depressive symptoms, but also increased KYN/tryptophan ratios, reflecting higher IDO activity, as well as increased KYN/KA ratios, corresponding to the degree of neurotoxicity involved [61].

2.2. Feeding the Fire: Proinflammatory Neuroendocrine Signaling

Certainly, the impact of CI on depression is hardly limited to changes in the brain; it is widely recognized as a pivotal pathophysiologic component in atherosclerosis, by potentiating vascular chemotaxis, release of growth factors, and proliferation of vascular smooth muscle cells, among other mechanisms. This underlines the shared mechanisms underlying the pathogenesis of depression and CVD [62]. Participants with depression also appear to have increased expression of VCAM-1 and other vascular adhesion and thrombogenic molecules in endothelial cells [63-67]. Hyperactivation of the HPAA and hypercortisolemia have been related to the downregulation of endothelial nitric oxide synthase (eNOS), impairing relaxation of vascular walls [68, 69]. Other possible alterations of vascular tone in depression include decreased vagal tone with sympathetic hyperactivation, with increased non-selective α-adrenergic and β-adrenergic activity in the cardiovascular system [70, 71]. Platelet dysfunction has also been described in depression, including augmented intraplatelet traffic of calcium and other disruptions in signaling, upregulation of α-adrenergic and 5HT2A receptors, P-selectin, glycoprotein IIb/IIIa and β-thromboglobulin, and downregulation of serotonin transporters [72-74]. Indicators of endothelial dysfunction in depressed patients may improve with antidepressant therapy. López-Vilchez et al. found participants with depression to display higher levels of circulating endothelial cells, VCAM-1 and soluble von Willebrand factor, which decreased gradually along 24 weeks in treatment with escitalopram [63].

In addition, IR is a pivotal mediator between CI, CVD and depression. IR, defined as decreased peripheral tissue responsiveness to insulin signaling [75], is promoted by proinflammatory mediators, particularly by inducing serine phosphorylation of IRS-1 [76], as well as ectopic fat deposition in the liver and muscle tissue [77]. Typical hormonal changes of depression, such as increased catecholamine and glucocorticoid signaling, can also promote IR. This impact may be most marked regarding the cognitive symptoms of depression, as described by Austin et al. in a cohort of 328 patients [78]. This reduced sensitivity entails hyperinsulinemia, which in turn yields deleterious effects on all organ systems, and predisposes to numerous cardiometabolic disturbances such as obesity, hyperglycemia, dyslipidemia and hypertension, among others [79]. In turn, these are all promoters of CI, thus constituting a vicious cycle involving depression, CI, and IR (Fig. 3) [80].

Obesity is a powerful enhancer of IR and all its associated disturbances. Adipose tissue has been recognized as an immunologically active organ, through the secretion of proinflammatory cytokines and adipokines: leptin, resistin and adiponectin [81]. Leptin plays a physiological role, where it promotes satiety in accordance with increasing adipose tissue deposits. However, in obesity, leptin resistance is a frequent finding, favoring an energetic imbalance towards excess [82]. Leptin also intervenes in the pathogenesis of depression by potentiating HHPA activation [83] and promoting the expression of IL-6 and TNFα [84]. Resistin and adiponectin display opposite effects regarding CI and energetic homeostasis, with the former being proinflammatory and upregulated in obesity, and the latter being anti-inflammatory and upregulated by weight loss, with decreased expression in obesity [85]. Although the role of resistin in depression remains obscure; adiponectin expression has been found to be downregulated by glucocorticoid signaling, which could further favor obesity and CI in depression [86]. Altered adipokine levels have been widely reported in depressed patients, especially increased leptin and decreased adiponectin [87]. These mediators have been proposed as putative biomarkers for depression, though variables such as the severity of depression and obesity may be important confounders in this context as determined in a systematic review and meta-analysis by Carvalho et al. [88]. Adipokines may be predictors of antidepressant therapy outcomes, although similar concerns remain [89]. Because IR is a natural stepping stone in the development of Type 2 Diabe-
tes Mellitus (DM2), and owing to the added psychosocial challenges by the disease [90], it is unsurprising that the prevalence of depression is two to three times greater in diabetic patients [91]. DM2 majorly enhances all pathophysiologic components related to IR, CI, and obesity [92], which leads to potentiated neuroinflammation through the increased OS and deleterious microvascular and macrovascular changes [93]. Notoriously, brain structures involved in circuits related to suicidal behavior may be especially susceptible to damage in DM2 [91, 94, 95]. Hypertension is also closely related to IR: Angiotensin II, a key mediator in the renin-angiotensin-aldosterone system (RAAS) has been reported to modulate neuroprotection via AT2 receptors in neurons [96-100]. In addition, activation of AT1 receptor favors CI and OS by triggering the release of TNFα and other cytokines, activation of the NADPH-oxidase complex and NF-κB, and expression of iNOS and cyclooxygenase-2 (COX-2) [101-103].

The sum of these CI- and IR-related risk factors results in endothelial dysfunction [104], which has also been associated with depression. Measures of endothelial dysfunction such as intima-media thickness and flow-mediated dilation have been inversely correlated with the severity of depression [105, 106]; highlighting the progressive impact of the immunometabolic disturbances in the evolution of depression.

3. IMPACT OF ESTABLISHED TREATMENTS FOR CARDIOVASCULAR DISEASE IN THE MANAGEMENT OF DEPRESSION

There have been significant advances in the elucidation of the mechanistic interplay between depression and CVD [4], and the effect of antidepressants on discrete cardiometabolic variables has been outlined [107]. Nevertheless, the effects of antidepressants on specific cardiovascular outcomes remain undetermined [108]. The same is true for the
Table 1. Summary of key evidence regarding established treatments for cardiovascular disease in the management of depression.

| Class                      | Compounds (REF)                        | Methodology                                                                 | Relevant Results                                                                                                                                                                                                 |
|----------------------------|----------------------------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Non-steroidal anti-inflammatory drugs | NSAIDs, cytokine inhibitors (113)       | Systematic review and meta-analysis on 14 trials (6262 participants), 10 with NSAIDs and 4 with cytokine inhibitors assessing their use for depression and depressive symptoms. | Anti-inflammatory treatment was associated with reduced depressive symptoms (SMD, -0.34; 95% CI, -0.57 to -0.11; I²=90%). This was most prominent for celecoxib (SMD, -0.29; 95% CI, -0.49 to -0.08; I²=73%) on remission (OR, 7.89; 95% CI, 2.94 to 21.17; I²=0%) and response (OR, 6.59; 95% CI, 2.24 to 19.42; I²=0%). |
|                            | ASA + SSRI (117)                        | Pilot open-label trial which included 24 patients with major depression who had not responded to treatment during at least 4 weeks with an SSRI, and received add-on ASA 160 mg/day during 4 weeks. | Of the 21 patients who completed the study, 52.4% showed a significant response to the ASA + SSRI combination; and 82% achieved remission by the end of the study. Significant changes were observed in the HDRS ratings, with a baseline mean of 29.3±4.5 points, which decreased to 14.0±4.1 points by day 7 (P<0.0001). This trend persisted until the end of the study on day 28. |
| Statins                    | Lovastatin + Fluoxetine (124)          | Randomized, placebo-controlled trial which included 68 patients with major depressive disorder who received up to 40 mg/day of fluoxetine + lovastatin 30 mg/day or fluoxetine + placebo for 6 weeks. | Both groups obtained a significant reduction in HDRS scores, although this was greater in the fluoxetine + lovastatin group. The fluoxetine + lovastatin group had a baseline mean HDRS score of 28.9±6.86 points, which decreased to 16.3±5.03 by week 6 (P<0.05). |
|                            | Simvastatin + Fluoxetine (125)         | Double-blind, placebo-controlled trial which included 48 patients with moderate-severe depression which received fluoxetine 20-40 mg/day + simvastatin 20 mg/day or fluoxetine + placebo for 6 weeks. | Patients treated with fluoxetine + simvastatin had a significantly greater reduction in HDRS scores in comparison with the fluoxetine + placebo group. The reductions in HDRS scores for the former were of 8.04±4.09 by week 2 (P<0.01), 13.45±4.58 by week 4 (P<0.02), and 18.5±7.1 by week 6 (P<0.02). No adverse effects were reported during the study. |
|                            | Various (128)                          | Systematic review and meta-analysis on 19 trials (3369 participants), 9 with thiazolidinediones, 5 with metformin, 2 with thiazolidinediones against metformin, 2 with incretin-based therapies and 1 with insulin, assessing their impact on depressive symptoms. | In comparison with controls, pioglitazone was associated with increased remission rates (27% versus 10%, P=17.3%, fixed-effect model: [OR] =3.3, 95% confidence interval [95% CI; 1.4, 7.8], P=0.008). |
| Antidiabetic drugs         | Pioglitazone (131)                     | Meta-analysis with 4 randomized controlled trials comprising 161 patients with a major depressive episode. | Pioglitazone was associated with reduced depressive symptoms compared to controls (pooled effect size = -0.68 (95% C.I., -1.12 to -0.24), p = .003, Nmax = 8, I² = 83.2%); while metformin was compared to controls. Female sex was a predictor for improvement of depressive symptoms with pioglitazone. |
|                            | Metformin (138)                        | Double-blind, randomized, placebo-controlled trial which included 58 patients with depression and DM2 who received metformin 1-2 g/day or placebo for 24 weeks. | Administration of metformin was associated with a decrease in MADRS (F1,112 = 26.43, p < 0.001) and HDRS-17 (F1,112 = 27.61, p < 0.001) scores compared to baseline. In addition, at week 24, patients on metformin showed a significant improvement in cognitive function; with improved WMS-R scores in the verbal memory index (F1,112 = 22.19, p < 0.001), visual memory index (F1,112 = 10.53, p < 0.01), general memory index (F1,112 = 4.27, p <0.05), attention and concentration index (F1,112 = 12.62, p < 0.01), and delayed memory index (F1,112 = 19.84, p < 0.001). |
| Antihypertensive drugs     | Irbesartan + Fluoxetine (145)          | Preclinical study on rats subjected to an unpredictable mild stress protocol which were treated with irbesartan 40 mg/kg and/or fluoxetine 25 mg/kg in monotherapy or combination. Behavioral responses were assessed with MFST and TST at week 6. | Treatment with Irbesartan + Fluoxetine decreased immobility time (166s, p<0.001) in the TST, whereas it increased swimming (184.16s, p<0.001) and climbing times (184.16s, p<0.001) and decreased immobility time (8.5s, p<0.001) in the MFST. |

(Table 1) contd....
effects of cardiometabolic treatments on depression [109, 110], remaining an equally provoking, yet uncertain field of research (Table 1).

Non-steroidal anti-inflammatory drugs (NSAIDs) have been posited as potentially useful modulators of CI in depression due to their relatively selective pharmacodynamics [111, 112]. Selective COX-2 inhibitors may be the most promising in this regard. In a systematic review and meta-analysis, celecoxib appeared to significantly decrease depressive symptoms without notable adverse effects, in contrast with other NSAIDs and cytokine inhibitors [113]. Similar findings have been supported by multiple trials [114-116]. However, different NSAIDs appear to yield different results in depression. In a pilot study on patients with treatment-resistant depression (TRD), 52.4% of participants responded positively to the coadministration of acetylsalicylic acid with a selective serotonin reuptake inhibitor (SSRI) [117]. In contrast, other studies with differing combinations of non-selective NSAIDs and SSRIs have failed to obtain similar results [118-121]. At any rate, these findings should be interpreted with caution, as the available trials were short and executed on younger participants. Indeed, the need for optimization and uniformity of trial methodology is a recurring theme in the assessment of NSAIDs and several other treatments for depression.

Empirical evidence shows that the use of statins is associated with a decreased risk of depression in adults [122]. This effect has been hypothesized to be mediated by the reduction of excitotoxicity and OS through antagonism of NMDA receptors and IDO [123]. Several small, short, placebo-controlled trials have reported improved antidepressant responses in participants treated with fluoxetine + lovastatin [124], fluoxetine + simvastatin [125], and cilostamide + simvastatin [126]. Yet, again, future trials require larger samples and longer duration to better ascertain the efficacy of statins as antidepressant adjuvants. Clinical research on other hypolipidemic drugs in depression is scarce, and preclinical findings seem discouraging [127].

A variety of antidiabetic drugs have also been evaluated in depression [128]. Most research has focused on thiazolidinediones, which have powerful anti-inflammatory activity via activation of PPAR-γ and downregulation of eNOS [129] and have shown antidepressant activity in rat and mouse models [130]. In a meta-analysis, these drugs displayed a pooled effect size of −0.68 (95% CI: −1.12 to −0.24) for symptom amelioration in depression [128]; and another supports the role of pioglitazone in improving the probability of remission [131]. Indeed, numerous studies have reported favorable results for the use of pioglitazone as an adjuvant to antidepressants [132-134]. Indeed, there is evidence that the antidepressant effect of pioglitazone is more durable when compared with other similar adjuvants, with trials as long as 24 weeks returning positive results [135]. However, it should be noted that these studies mostly included individuals with obesity, DM2 and other established metabolic disorders. Thus, the effects of pioglitazone in depression more metabolically healthy participants remain to be ascertained.

Metformin also has notorious anti-inflammatory activity, by decreasing expression of NF-κB via AMPK-dependent and independent pathways, as well as improving energetic balance irrespective of the presence of DM2 and other metabolic disturbances [136, 137]. In a 24-week double-blind, placebo-controlled, randomized clinical trial of patients with DM2, the administration of metformin significantly improved depressive symptoms in comparison to placebo [138]. However, these results are not consistent across trials [139]; and pioglitazone may be a superior alternative: In a 6-week double-blind study on obese patients with depression and polycystic ovary syndrome and depression, monotherapy with pioglitazone granted greater improvement in depressive symptoms than monotherapy with metformin [140]. Similarly to pioglitazone, the antidepressant potential of metformin in metabolically healthy participants remains rather unexplored. Research on other antidiabetic drugs including glibenclamide [141], liraflutide [142], and sitagliptin [143] for depression remains chiefly in preclinical stages.

Concerning antihypertensive drugs, amounting preclinical and clinical evidence suggests a link between modulation of the RAAS to intervene in the pathophysiology of depression [144-150]. Angiotensin-converting enzyme inhibitors (ACEI), and angiotensin-receptor blockers (ARB) may impact depression by reducing CI and OS, and promoting neurogenesis [148]. Out of all classes of antihypertensive drugs, only ACEI and ARB were associated with decreased risk for hospitalization related to a mood disorder in a large retrospective study by Boal et al. [149]. Likewise, in the HUNT study from Norway, hypertensive patients treated with ACEIs had lower odds of displaying symptoms of depression [150]. However, future studies accounting for confounders
such as disease severity, comorbidities and polypharmacy should clarify the true role of antihypertensive drugs as antidepressant adjuvants.

Finally, in recent decades, omega-3 fatty acids received widespread acceptance as augmenting agents for antidepressant therapy [151-154]. These molecules have been recognized due to their direct anti-inflammatory and antioxidant properties [155]. They may also participate in the neurobiology of depression by modulating the expression and functionality of serotonin and dopamine receptors [156]. Nevertheless, more recent meta-analyses have reframed the role of these molecules for depression, with reports of small, non-significant effect sizes [157-159]. The variable concentrations of eicosapentaenoic acid (EPA) in omega-3 preparations may be an important intervening factor in this scenario [160]. A meta-analysis by Martins et al. [161] found omega-3 fatty acids to enhance antidepressant response, yet with great variability depending on EPA contents: Only studies with EPA contents ≥60% showed significant antidepressant effects, in contrast with studies using EPA contents <60%. This highlights the importance of continuous evaluation of novel antidepressant alternatives in clinical settings.

4. POTENTIAL PHARMACOLOGICAL CANDIDATES FOR THE JOINT MANAGEMENT OF DEPRESSION AND CARDIOVASCULAR DISEASE

In addition to the use of antidepressants for CVD and the use of cardiometabolic treatments for depression, other pharmacological options have been studied in an effort to attack both problems simultaneously. CI remains a prime

---

**Table 2** Summary of key evidence regarding new pharmacological candidates for the joint management of depression and cardiovascular disease.

| Class                  | Compounds (REF) | Methodology                                                                 | Relevant results                                                                 |
|------------------------|-----------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Interleukin antagonists | Ustekinumab (164) | Multicentric, double-blind, randomized, placebo-controlled trial where 1230 patients with psoriasis who received ustekinumab 45 mg, ustekinumab 90 mg, or placebo for 24 weeks, and had their depressive and anxious symptoms evaluated. | At week 12, treatment with ustekinumab was associated with significant reductions in HADS scores both in patients who received 45 mg (1.7 ± 3.1) and 90 mg (2.1 ± 3.4); P<0.001. |
|                        | Dupilumab (165) | Double-blind, randomized, placebo-controlled trial with 380 patients with atopic dermatitis who were treated with dupilumab 100 mg, 200 mg or 300 mg, or placebo for 16 weeks, and had their depressive and anxious symptoms evaluated. | A significant reduction in depressive and anxious symptoms was observed at 16 weeks in patients treated with dupilumab (P<0.001), with 66.7-75% reductions in the treated groups vs 22.2% in the placebo groups. |
|                        | Infliximab (166) | Double-blind, randomized, placebo-controlled, 12-week trial with 60 patients with major depression who received three infusions of infliximab (5 mg/kg, at baseline and weeks 2 and 6) or placebo. | Of patients with high-sensitivity C-reactive protein levels ≥5 mg/L, 62% showed an improvement of ≥50% in depressive symptoms as assessed with the HDRS. |
| Antioxidants           | NAC (171)       | Systematic review including 65 studies on the use of NAC for various neuropsychiatric disorders, of which 2 were on depressive disorder. | The grade of recommendation for depressive disorder was B. Authors highlight the need for further controlled studies and longer follow-up for assessing consistent improvement. |
| Vitamins               | Various (174)   | Systematic review and meta-analysis with 40 studies on various nutraceuticals, including 9 on folate, folic acid, methylfolate, or a combination of folic acid with vitamins B6 and B12. | The pooled effect size was 0.49 inconsequential, with a non-significant difference between folic acid and placebo (p=0.23; z=1.19, 95% confidence interval [CI], −0.31 to 1.29). Similarly, isolated analysis of methylfolate yielded a non-significant effect (p=0.52; z=1.15, 95% CI, −0.22 to 0.83). |
|                        | L-Methylfolate (175) | Naturalistic clinical trial with 554 patients, of which 502 received L-methylfolate as adjunctive therapy, and 52 as monotherapy. | A mean reduction of 8.5 points (58.2% decrease) was found in patients’ PHQ-9 score (mean baseline PHQ-9 score=14.6, mean follow-up PHQ-9 score=6.1; P = .000). In addition, 376 patients (67.9%) showed treatment response, while 253 (45.7%) achieved remission after an average of 95 days in treatment. |
| Nutritional supplements | SAMe (185)      | Double-blind, randomized, placebo-controlled, 12-week trial on 189 patients with MDD who were treated with SAMe 1600-3200 mg/d, escitalopram 10-20 mg/d or placebo. | All treatment arms showed a significant reduction in HDRS scores (P<0.001); with a reduction of mean scores from 18.98 ± 5.09 to 12.79 ± 7.38 (p < 0.001) in the group treated with SAMe. Remission rates were 28% for SAMe, 28% for escitalopram, and 17% for placebo. |

Abbreviations: HADS: Hospital anxiety and depression scale; HDRS: Hamilton depression rating scale; NAC: N-acetylcysteine; PHQ-9: Patient Health Questionnaire-9; SAMe: S-adenosylmethionine; MDD: Major depressive disorder.
therapeutic target in this context, with numerous other forms of anti-inflammatory agents being studied in these circumstances (Table 2) [119]. Immunotherapy may be a frontrunner in this regard, as it has been ascertained to diminish cardiovascular risk in patients with rheumatoid arthritis and other similar conditions [162, 163]. Immunotherapy may also be useful in depression: in a randomized, double-blind, placebo-controlled, 24-week trial carried out on 1230 patients with moderate-severe psoriasis, treatment with ustekinumab, an IL-12 and IL-23 antagonist, was associated with significant improvement of anxious and depressive symptoms [164]. In a similar study on 380 patients with severe atopic dermatitis, the administration of dupilumab, an IL-4 antagonist, was also associated with a significant reduction of anxious and depressive symptoms [165]. Indeed, to date, improvement of depression is a secondary outcome in most trials assessing immunotherapeutics. Nevertheless, a small randomized, double-blind, placebo-controlled, 12-week trial by Raison et al. [166] evaluating the use of TNFa antagonist infliximab for TRD reported more promising results. In this study, participants in the control group with initial hs-CRP levels >5 mg/L showed >50% improvement of depressive symptoms. Future studies should explore more in-depth the utility of immunotherapy in populations with depression without other inflammatory comorbidities.

Various nutritional supplements have also been studied in the management of depression. N-acetylcysteine (NAC) has particularly ignited research interest given its role as an antioxidant by replenishing glutathione levels, as well as being an immunomodulator, and regulator of glutamate and dopamine neurotransmission [167, 168]. Its antioxidant properties have proved useful in the management of CVD [169, 170]. Current clinical evidence on NAC for depression is considered only preliminary, with further confirmatory research required, especially on the exploration of optimal dosing schemes and candidate selection, as determined in a systematic review by Deepmala et al. [171]. Indeed, clinical outcomes remain equivocal, with trials reporting improvement of depressive symptoms without changes in inflammatory biomarkers [172]; or major uncertainty in regards to sufficient and optimal duration of administration [173].

Finally, folate has also been studied substantially in the context of depression. A large systematic review and meta-analysis concluded that available data assessing folate, folinic acid and methylfolate on this matter are contradictory, without any determinant evidence in favor of folate, and relatively more positive results for methylfolate [174]. Interestingly, in isolated clinical trials methylfolate appears to be beneficial both alone and as adjunctive therapy [175, 176]. This should warrant further investigation, as in the National Health and Nutrition Examination Survey (NHANES), Americans with low serum folate were found to be at increased risk for depression [177]. Future continued investigation is essential, as folic acid derivates may aid in the prevention of CVD by intervening in the metabolism of homocysteine, a known biomarker for cardiovascular risk [178].

Research on the use of other supplements with joint effects on depression and CVD, such as zinc and various vitamins, is currently underway [179, 180]. In this setting, S-adenosylmethionine (SAMe) represents a peculiar case, as it has raised concerns of increased cardiovascular risk, due to being a precursor of homocysteine [181]. In animal models, SAMe has been shown to increase the synthesis of monoamines, modulate neurotransmission and improve membrane fluidity [182]. Although current findings suggest SAMe to be innocuous regarding cardiovascular risk [183], evidence regarding its efficacy for depression is inconsistent, and numerous studies have failed to show significant benefits to its use [184, 185].

CONCLUSION

The integration of the management of depression and CVD on the basis of their shared pathophysiologic components is an attractive prospect. However, great gaps in currently available preclinical and clinical knowledge preclude the introduction of novel alternatives in this regard at this time. CI is undoubtedly the most appealing target in this context. Although the need for further clinical investigation is indisputable, researchers should mind the common research design problems frequently seen in clinical psychiatry. Indeed, beyond the necessity for more homogenized methodology and clear study outcomes, a wide spectrum of questions must be addressed earnestly, ranging from the practical, in population selection and follow-up duration; to the conceptual, including the very definition of TRD, remission and relapse [186, 187].

The resolution of these conundrums is necessary to improve the quality of research in clinical psychiatry, and consequently facilitate the introduction of revolutionizing therapeutic measures in depression, CVD, and other associated conditions. In the meantime, lifestyle recommendations, in the form of sufficient physical activity and dietary modifications, may be invaluable, safe and useful tools in the treatment of depression, CVD, and many related immunometabolic disorders.

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Friedrich, M.J. Depression Is the Leading Cause of Disability Around the World. JAMA, 2017, 317(15), 1517. http://dx.doi.org/10.1001/jama.2017.3826 PMID: 28418490

[2] Joseph, P.; Leong, D.; McKee, M.; Anand, S.S.; Schwalm, J-D.; Teo, K.; Mente, A.; Yusuf, S. Reducing the Global Burden of Cardiovascular Disease, Part I: The Epidemiology and Risk Factors. Circ. Res., 2017, 121(6), 677-694. http://dx.doi.org/10.1161/CIRCRESAHA.117.308903 PMID: 28860318
Depression as an Immunometabolic Disorder

Phenotypes

http://dx.doi.org/10.1017/neu.2016.69 PMID: 28112016

Croglia and neurons: from survival to neuropathology. J. Neurosci. Biol., 2015, 12(3), 135-143.

http://dx.doi.org/10.1010/jnsc.2016.159(Suppl. 2), 136-153.

http://dx.doi.org/10.1010/jnsc.2016.159(Suppl. 2), 136-153.

http://dx.doi.org/10.1010/jnsc.2016.147(Suppl. 1), 135-143.

http://dx.doi.org/10.1010/jnsc.2016.147(Suppl. 1), 135-143.

http://dx.doi.org/10.1010/jnsc.2016.147(Suppl. 1), 135-143.

http://dx.doi.org/10.1010/jnsc.2016.147(Suppl. 1), 135-143.
[43] Siomek, A. NF-κB signaling pathway and free radical impact. Acta Biochim. Pol., 2012, 59(3), 323-331. http://dx.doi.org/10.18388/abp.2012.2116 PMID: 22855720

[44] Maes, M.; Kubera, M.; Mihaylova, I.; Geffard, M.; Galecki, P.; Levinis, J-C; Berk, M. Increased autoimmune responses against autoreceptors modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression. J. Affect. Disord., 2013, 149(1-3), 23-29. http://dx.doi.org/10.1016/j.jad.2012.06.039 PMID: 22898471

[49] Turner, C.A.; Akil, H.; Watson, S.J.; Evans, S.J. The fibroblast growth factor system and mood disorders. Biol. Psychiatry, 2006, 59(12), 1128-1135. http://dx.doi.org/10.1016/j.biopsych.2006.02.026 PMID: 16631131

[50] Angelucci, F.; Brené, S.; Mathé, A-A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry, 2005, 10(4), 345-352. http://dx.doi.org/10.1038/sj.mp.4001637 PMID: 15655562

[51] Molenikij, M.L.; Bus, B.A.; Spinovhen, P.; Penninx, B.W.; Kenis, G.; Prickaerts, J.; Voshaar, R.C.; Elzinga, B.M. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol. Psychiatry, 2011, 16(11), 1088-1095. http://dx.doi.org/10.1038/mp.2010.98 PMID: 20856249

[52] Lebrec, P.; Talarowska, M.; Anderson, G.; Berk, M.; Maes, M. Mechanisms underlying neurocognitive dysfunctions in recurrent major depression. Med. Sci. Monit., 2011, 27, 1535-1547. http://dx.doi.org/10.12699/MS.893176 PMID: 26017336

[54] Vavilová, M.; Duračková, Z.; Trebatická, J. Markers of Oxidative Stress and Neuroprogression in Depression Disorder. Oxid. Med. Cell. Longev., 2015, 2015, 898393. http://dx.doi.org/10.1155/2015/898393 PMID: 26078821

[55] Aydemir, O.; Deveci, A.; Taneli, F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34(2), 261-265. http://dx.doi.org/10.1016/j.pnpbp.2010.12.017 PMID: 21185346

[59] Maes, M.; Kubera, M.; Obuchowiczwa, E.; Goehler, L.; Brzeszcz, J. Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuroendocrinol. Lett., 2011, 32(1), 7-24. PMID: 21407167

[60] Vavilová, M.; Kubera, M.; Obuchowiczwa, E.; Goehler, L.; Brzeszcz, J. Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuroendocrinol. Lett., 2011, 32(1), 7-24. PMID: 21407167

[62] Freire, R.; Klein, E.; Ben Shachar, D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol. Psychiatry, 2004, 55(7), 676-684. http://dx.doi.org/10.1016/j.biopsych.2003.12.012 PMID: 15038995

[63] Gervasoni, N.; Aubry, J-M.; Bondolfi, G.; Osieck, S.; Schwald, M.; Bertsch, G.; Kerege, F. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology, 2005, 51(4), 234-238. http://dx.doi.org/10.1155/2005/898393 PMID: 21185346

[64] Lugo-Huitrón, R.; Ugale Muñiz, P.; Pineda, B.; Pedraza-Chaverri, J.; Rios, C.; Perez-de la Cruz, V. Quinolinic acid: an endogenous neurotoxin with multiple targets. Oxid. Med. Cell. Longev., 2013, 2013, 104024. http://dx.doi.org/10.1155/2013/104024 PMID: 24089628

[65] Vavilová, M.; Duračková, Z.; Trebatická, J. Markers of Oxidative Stress and Neuroprogression in Depression Disorder. Oxid. Med. Cell. Longev., 2015, 2015, 898393. http://dx.doi.org/10.1155/2015/898393 PMID: 26078821

[66] Maes, M.; Kubera, M.; Obuchowiczwa, E.; Goehler, L.; Brzeszcz, J. Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuroendocrinol. Lett., 2011, 32(1), 7-24. PMID: 21407167

[67] Aydemir, O.; Deveci, A.; Taneli, F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34(2), 261-265. http://dx.doi.org/10.1016/j.pnpbp.2010.12.017 PMID: 21185346

[68] Lugo-Huitrón, R.; Ugale Muñiz, P.; Pineda, B.; Pedraza-Chaverri, J.; Rios, C.; Perez-de la Cruz, V. Quinolinic acid: an endogenous neurotoxin with multiple targets. Oxid. Med. Cell. Longev., 2013, 2013, 104024. http://dx.doi.org/10.1155/2013/104024 PMID: 24089628

[69] Maes, M.; Mihaylova, I.; Ruyter, M.D.; Kubera, M.; Bosmans, E. The immune effects of TRYCATs (tryptophan catabolites) on the IDO pathway: relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation. Neuroendocrinol. Lett., 2007, 28(6), 826-831. PMID: 18063923

[70] Aydemir, O.; Deveci, A.; Taneli, F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34(2), 261-265. http://dx.doi.org/10.1016/j.pnpbp.2010.12.017 PMID: 21185346

[71] Vavilová, M.; Duračková, Z.; Trebatická, J. Markers of Oxidative Stress and Neuroprogression in Depression Disorder. Oxid. Med. Cell. Longev., 2015, 2015, 898393. http://dx.doi.org/10.1155/2015/898393 PMID: 26078821

[72] Maes, M.; Mihaylova, I.; Ruyter, M.D.; Kubera, M.; Bosmans, E. The immune effects of TRYCATs (tryptophan catabolites) on the IDO pathway: relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation. Neuroendocrinol. Lett., 2007, 28(6), 826-831. PMID: 18063923

[73] Maes, M.; Leonard, B.E.; Myint, A.M.; Kubera, M.; Verkerk, R. The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35(3), 702-721. http://dx.doi.org/10.1016/j.pnpbp.2010.10.004 PMID: 24089628
Depression as an Immunometabolic Disorder

Phosphorylation of insulin receptor substrate

Draznin, B. Molecular mechanisms of insulin resistance: serine kinase phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. *Diabetes*, **2006**, *55*(8), 2392-2397.

http://dx.doi.org/10.2337/db06-0391 PMID: 16873706

Snel, M.; Jonker, J.T.; Schoones, J.; Lamb, H.; de Roos, A.; Pijl, H.; Smit, J.W.; Meinders, A.E.; Jazet, I.M. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventional. *J. Intern. Med.*, **2012**, *12*, 983184.

http://dx.doi.org/10.1155/2012/983184 PMID: 22675355

Bloomgarden, Z.T. World congress on insulin resistance. *Diabetes, Obesity*, **2010**, *3*(1), 89-100.

http://dx.doi.org/10.1111/j.1463-1326.2010.01315.x PMID: 20495452

Austria, W.; Gordon, J.L.; Lavoie, K.L.; Arsenault, A.; Dasgupta, K.; Bacon, S.L. Differential association of insulin resistance with cognitive and somatic symptoms of depression. *Diabet. Med.*, **2014**, *3*(1), 99-100.

http://dx.doi.org/10.1111/dme.12465 PMID: 24754892

McCracken, E.; Monaghan, M.; Sreenivasan, S. Pathophysiology of the metabolic syndrome. *Clin. Dermatol.*, **2014**, *36*(1), 14-20.

http://dx.doi.org/10.1016/j.clintherap.2017.09.004 PMID: 29241747

Webb, M.; Davies, M.; Ashra, N.; Bodicoat, D.; Brady, E.; Webb, D.; Moulton, C.; Ismail, K.; Khunti, K. The association between depressive symptoms and insulin resistance, inflammation and adiposity in men and women. *PLOS One*, **2017**, *12*(11), e0187448.

http://dx.doi.org/10.1371/journal.pone.0187448 PMID: 29190710

Mancuso, P. The role of adipokines in chronic inflammation. *ImmunoTargets Ther.*, **2016**, *5*, 47-56.

http://dx.doi.org/10.2147/ITT.S73231 PMID: 27529061

Sainz, N.; Barrenetxea, J.; Moreno-Aliaga, M.J.; Martinez, J.A. Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. *Metabolism*, **2015**, *64*(1), 35-46.

http://dx.doi.org/10.1016/j.metabol.2014.10.015 PMID: 25497342

Cimmino, M.A.; Andraghetti, G.; Briatore, L.; Salani, B.; Parodi, M.; Cutillo, M.; Cordera, R. Changes in adiponectin and leptin concentrations during glucocorticoid treatment: a pilot study in patients with polymyalgia rheumatica. *Ann. N. Y. Acad. Sci.*, **2010**, *1193*, 160-163.

http://dx.doi.org/10.1111/j.1749-6632.2010.05364.x PMID: 20398023

Agrawal, S.; Collapuradi, S.; Su, H.; Gupta, S. Leptin activates human B cells to secrete TNF-α, IL-6, and IL-10 via JAK2/STAT3 and p38MAPK/ERK1/2 signaling pathway. *J. Clin. Immunol.*, **2011**, *31*(3), 472-478.

http://dx.doi.org/10.1007/s10875-010-9507-1 PMID: 21243519

Taylor, V.H.; Macqueen, G.M. The Role of Adipokines in Understanding the Associations between Obesity and Depression. *J. Obes.*, **2010**, *1*, 6.

http://dx.doi.org/10.1155/2010/748048 PMID: 20978882

Sukumaran, S.; Dubois, D.C.; Usko, W.J.; Almon, R.R. Glucocorticoid effects on adiponectin expression. *Vitam. Horm.*, **2012**, *90*, 163-186.

http://dx.doi.org/10.1016/B978-0-12-398313-8.00007-5 PMID: 23171776

Milaneschi, Y.; Lamer; F.; Drent, M.L.; Penninx, BWJH Leptin Dysregulation Is Specifically Associated With Major Depression With Atypical Features: Evidence for a Mechanism Connecting Obesity and Depression. *Biol. Psychiatry.*, **2017**, *81*(9), 807-814.

Carvalho, A.F.; Rocha, D.Q.C.; McIntyre, R.S.; Mesquita, L.M.; Köhler, C.A.; Hyphantis, T.N.; Sales, P.M.; Machado-Vieira, R.; Berk, M. Adipokines as emerging depression biomarkers: a systematic review and meta-analysis. *J. Psychiatr. Res.*, **2014**, *59*, 28-37.

http://dx.doi.org/10.1016/j.jpsychires.2014.08.002 PMID: 25183029

Machado-Vieira, R.; Gold, P.W.; Luckenbaugh, D.A.; Ballard, E.D.; Richards, E.M.; Henter, I.D.; De Sousa, R.T.; Waksman, B.; Niciu, M.J.; Bacon, S.L. Differential association of insulin resistance with cognitive and somatic symptoms of depression. *Diabet. Med.*, **2017**, *221*(1), 127-133.

http://dx.doi.org/10.1038/mp.2016.36 PMID: 27046644

Yu, Y.; Y-Hua, H.; Hong, L. Depression in newly diagnosed type 2 diabetes. *Int. J. Diabetes Dev. Ctries.*, **2010**, *30*(2), 102-104.

http://dx.doi.org/10.4103/0973-3930.62601 PMID: 20535315

Bădescu, S.V.; Tătaru, C.; Kobylinska, L.; Georgescu, E.L.; Zaihu, D.M.; Zăgrean, A.M.; Zăgrean, L. The association between Diabetes mellitus and Depression. *J. Med. Life*, **2016**, *9*(2), 120-125.

PMID: 27453739
Physiological mechanisms linking depression and atherosclerosis: Pizzi, C.; Santarella, L.; Costa, M.G.; Manfrini, O.; Flacco, M.E.; Labandeira, M.; Curran, J.I. Low interleukin-1β and serum IL-6 levels in patients with major depressive disorder. Biol. Psychiat. 2014, 75(13), 1298-1304.

Results of a double-blind, randomized, placebo controlled, add-on study. JAMA Psychiatry. 2014, 71(12), 1381-1391.

http://dx.doi.org/10.1001/jamapsychiatry.2014.1611 PMID: 25320282

Hare, D.L.; Toubousi, S.R.; Johansson, P.; Jaarsma, T. Depression and cardiovascular disease: a clinical review. Eur. Heart J., 2014, 35(21), 1365-1372.

http://dx.doi.org/10.1002/eurheartj.eht462 PMID: 24282187

Baune, B.T. Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation? Curr. Top. Behav. Neurosci., 2017, 31, 303-319.

http://dx.doi.org/10.1007/7854_2016_19 PMID: 27405497

Eyre, H.A.; Air, T.; Proctor, S.; Rositano, S.; Budge, S.; Baune, B.T. A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2015, 57, 11-16.

http://dx.doi.org/10.1016/j.pnpbp.2014.10.003 PMID: 25455584

Köhler, O.; Benus, M.E.; Nordentoft, M.; Farkouh, M.E.; Iyengar, R.L.; Mors, O.; Krogh, J. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014, 71(12), 1381-1391.

http://dx.doi.org/10.1001/jamapsychiatry.2014.1611 PMID: 25320282

[20] Abbasi, S.H.; Hosseini, F.; Modabbernia, A.; Ashrafi, M.; Akhondzadeh, S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J. Affect. Disord., 2012, 141(2-3), 308-314.

http://dx.doi.org/10.1016/j.jad.2012.03.033 PMID: 22516310

[21] Müller, N.; Schwarz, M.J.; Dehning, S.; Douhe, M.; Cerovecki, A.; Goldstein-Müller, B.; Spellmann, I.; Heizel, G.; Maino, K.; Klein-dienst, N.; Müller, H.J.; Arolt, V.; Riedel, M. The cyclooxygenase 2 inhibitor celecoxib has therapeutic effects in major depression: a systematic review and meta-analysis of randomized clinical trials. Mol. Psychiatry. 2006, 11(7), 680-684.

http://dx.doi.org/10.1038/sj.mp.4001805 PMID: 16491331

[22] Akhondzadeh, S.; Jahari, S.; Raisi, F.; Nasiri, A.A.; Ghoreishi, A.; Salehi, B.; Mohhebian-Rasa, S.; Raznahan, M.; Kamalipour, A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress. Anxiety. 2009, 26(7), 607-611.

http://dx.doi.org/10.1002/dca.20589 PMID: 19496103

[23] Hendelwicz, J.; Krön, P.; Oswald, P.; Souery, D.; Alboni, S.; Brunello, N. Shortened onset of action of antidepressants in major depression treated with acetylsalicylic acid augmentation: a pilot open-label study. Int. Clin. Psychopharmacol., 2006, 21(4), 227-231.

http://dx.doi.org/10.1097/00004850-200607000-00005 PMID: 16687994
Depression as an Immunometabolic Disorder

Uher, R.; Carver, S.; Power, R.A.; Mors, O.; Maier, W.; Rietschel, M.; Hauser, J.; Dernovsek, M.Z.; Heningsberg, N.; Souery, D.; Placentino, A.; Farmer, A.; McGruffin, P. Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. *Psychol. Med.*, 2012, 42(10), 2027-2035.

Paceo, J.A.; Jacka, F.N.; Williams, L.J.; Henry, M.J.; Nicholson, G.C.; Kotowicz, M.A.; Berk, M. Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. *Psychother. Psychosom.*, 2010, 79(5), 323-325.

Almeida, O.P.; Flicker, L.; Yeap, B.B.; Alfonso, H.; McCaul, K.; Hankey, G.J. Aspirin decreases the risk of depression in older men with high plasma homocysteine. *Transl. Psychiatry*, 2012, 2, e151.

Gallagher, P.J.; Castro, V.; Fava, M.; Weilburg, J.B.; Murphy, S.N.; Gainer, V.S.; Churchill, S.E.; Kohane, I.S.; Issifescu, D.V.; Smoller, J.W.; Perlis, R.H. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. *Am. J. Psychiatry*, 2012, 169(10), 1065-1072.

Redlich, C.; Berk, M.; Williams, L.J.; Sundquist, J.; Sundquist, K.; Li, X. Statin use and risk of depression: a Swedish national cohort study. *BMC Psychiatry*, 2014, 14, 348.

Kilic, F.S.; Ozatik, Y.; Kaygisiz, B.; Baydemir, C.; Erol, K. Acute antidepressant and anxiolytic effects of simvastatin and its mechanisms in rats. *Neurosciences (Riyadh)*, 2012, 17(1), 39-43.

Ghanizadeh, A.; Hedayati, A. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled clinical trial. *Depress. Anxiety*, 2013, 30(11), 1084-1088.

Gougol, A.; Zareh-Mohammadi, N.; Raheb, S.; Farokhnia, M.; Salimi, S.; Irannouri, N.; Yekhtaz, H.; Akhondzadeh, S. Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe depression: A double-blind placebo-controlled trial. *J. Psychopharmacol. (Oxford)*, 2015, 29(5), 575-581.

Köhler, O.; Gasse, C.; Petersen, L.; Instrup, K.G.; Nierenberg, A.A.; Mors, O.; Östergaard, S.D. The Effect of Concomitant Treatment With SSRIs and Statins: A Population-Based Study. *Am. J. Psychiatry*, 2016, 173(8), 807-815.

Fakhraei, N.; Javedan, R.; Nikoui, V.; Bakhhtiarian, A.; Poumgarsh Tehrani, S.S. Effect of Pioglitazone on PPAR-A Receptor Agonist, On Behavioral Dispari Associated With Exposure to Forced Swim in Rats. *Adv. J. Toxicol. Curr. Res.*, 2017, 1(2), 107-115.

Moulton, C.D.; Hopkins, C.W.P.; Ismail, K.; Stahl, D. Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials. *Psychoneuroendocrinology*, 2018, 99, 1-11.

Sadaghiani, M.S.; Javadi-Paydar, M.; Gharadeghi, M.H.; Fard, Y.Y.; Depour, A.R. Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway. *Behav. Brain Res.*, 2011, 224(2), 336-343.

Eissa Ahmed, A.A.; Al-Rashed, N.M.; Al-Rashed, N.M. Antidepressant-like effects of rosiglitazone, a PPARγ agonist, in the rat forced swim and mouse tail suspension tests. *Behav. Pharmacol.*, 2009, 20(7), 635-642.

Colle, R.; de Lanmitt, D.; Rotenberg, S.; Hozer, F.; Hardy, P.; Verstuyft, C.; Fève, B.; Corruble, E. Pioglitazone could induce remission in major depression: a meta-analysis. *Neuropsychiatr. Dis. Treat.*, 2013, 9, 9-16.
http://dx.doi.org/10.1038/tp.2016.29 PMID: 26978738

Martins, J.G.; Bentsen, H.; Puri, B.K. Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hanestad and updated meta-analysis. Mol. Psychiatry, 2012, 17(2), 1144-1149.

http://dx.doi.org/10.1038/mp.2012.25 PMID: 22488258

Puig, L. Cardiovascular Risk and Psoriasis: the Role of Biologic Therapy. Actas Dermosifiliogr., 2012, 103(10), 853-862.

http://dx.doi.org/10.1016/j.ad.2012.02.003

Roubille, C.; Mantel-Pelletier, J.; Harauoi, B.; Tardif, J-C.; Pelletier, J-P. Biologics and the cardiovascular system: a double-edged sword. Am. J. Ophthalmol., 2013, 156(1), 68-82.

http://dx.doi.org/10.2174/1871523101312010009 PMID: 23286291

Langley, R.G.; Feldman, S.R.; Han, C.; Schenkel, B.; Szapary, P.; Hsu, M-C.; Ornzone, J.P.; Gordon, K.B.; Kimball, A.B. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J. Am. Acad. Dermatol., 2010, 63(3), 457-465.

http://dx.doi.org/10.1016/j.jaad.2009.09.014 PMID: 20462664

Simpson, E.; Worm, M.; Soong, W.; Blauvelt, A.; Eckert, L.; Wu, R. Dupilumab Improves Patient-Reported Outcomes (PROs) in a Phase 2 Study in Adults with Moderate-to-Severe Atopic Dermatitis. J. Allergy Clin. Immunol., 2015, 135(3), AB167.

Raison, C.L.; Rutherford, R.E.; Woolwine, B.J.; Shou, C.; Schetler, P.; Drake, D.F.; Haroon, E.; Miller, A.H. A randomized controlled trial of the tumour necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry, 2013, 70(1), 31-41.

http://dx.doi.org/10.1001/2013.jamapsychiatry.4 PMID: 22945416

Dean, O.; Girolando, F.; Berk, M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci., 2011, 36(2), 78-86.

http://dx.doi.org/10.1503/jpn.100575 PMID: 21118657

Minarini, A.; Ferrari, S.; Galletti, M.; Giambalvo, N.; Perrone, D.; Roli, G.; Galieazzi, G.M. N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. Expert Opin. Drug Metab. Toxicol., 2017, 13(3), 279-292.

http://dx.doi.org/10.1080/17425255.2017.1215850 PMID: 27769614

Liu, C.; Lu, X-Z.; Shen, M-Z.; Xing, C-Y.; Ma, J.; Duan, Y-Y.; Yuan, L.J. N-Acetyl Cysteine improves the diabetic cardiac function: possible role of fibrosis inhibition. BMC Cardiovasc. Disord., 2015, 15(1), 84.

http://dx.doi.org/10.1186/s12872-015-0076-3 PMID: 26242742

Reyes, D.R.A.; Gomes, M.J.; Rosa, C.M.; Pagan, L.U.; Damotto, F.C.; Damotto, R.L.; Depra, I.; Campos, D.H.S.; Fernandez, A.A.H.; Martinez, P.F.; Okoshi, K.; Okoshi, M.P. N-Acetylcysteine improves the diabetogenic sensitivity of diabetic rats: Influence on reactive protein and cardiac remodeling during fructose-induced diabetes. J. Diabetes Res., 2014, 2014(95), 1-6.

http://dx.doi.org/10.1155/2014/957609 PMID: 25708061

Deepmula, nul; Slattery, J; Kumar, N Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev., 2015, 50, 294-321.

http://dx.doi.org/10.1016/j.nb.2015.01.002 PMID: 26312737

Hasebe, K.; Gray, L.; Bortolacci, C.; Panizzutti, B.; Mehebbi, M.; Kidnapillai, S.; Spolding, B.; Walder, K.; Berk, M.; Malhi, G.; Dodd, S.; Dean, O.M. Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor. Acta Neuropsychiatr., 2017, 29(6), 337-346.

http://dx.doi.org/10.1016/j.ajp.2016.12.003 PMID: 28318471

Sarris, J.; Murphy, J.; Mischoulon, D.; Papakostas, G.I.; Fava, M.; Berk, M; Ng, C.H. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Am. J. Psychiatry, 2016, 173(6), 575-587.

http://dx.doi.org/10.1176/appi.ajp.2016.15091228 PMID: 27131281
Depression as an Immunometabolic Disorder

[175] Shelton, RC; Sloan Manning, J; Barrentine, LW; Tipa, EV Assessing Effects of L-Methylfolate in Depression Management: Results of a Real-World Patient Experience Trial. Prim Care Companion CNS Disord., 2013, 15(4) PCC.13m01520.

[176] Papakostas, G.I.; Shelton, R.C.; Zajecka, J.M.; Etemad, B.; Rickels, K.; Clain, A.; Baer, L.; Dalton, E.D.; Sacco, G.R.; Schoenfeld, D.; Pencina, M.; Meisner, A.; Bottiglieri, T.; Nelson, E.; Mischoulon, D.; Alpert, J.E.; Barbee, J.G.; Zisook, S.; Fava, M. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am. J. Psychiatry, 2012, 169(12), 1267-1274. http://dx.doi.org/10.1016/j.biocel.2012.11071114 PMID: 23212058

[177] Nguyen, B.; Weiss, P.; Beydoun, H.; Kanchevila, V. Association between blood folate concentrations and depression in reproductive aged U.S. women, NHANES (2011-2012). J. Affect. Disord., 2017, 223, 209-217. http://dx.doi.org/10.1016/j.jad.2017.07.019 PMID: 28777954

[178] Bazzano, L.A. Folic acid supplementation and cardiovascular disease: the state of the art. Am. J. Med. Sci., 2009, 338(1), 48-49. http://dx.doi.org/10.1097/MAJ.0b013e3181aecedf6 PMID: 19593104

[179] Sosnowska, B.; Penson, P.; Banach, M. The role of nutraceuticals in the prevention of cardiovascular disease. Cardiovasc. Diagn. Ther., 2017, 7(Suppl. 1), S21-S31. http://dx.doi.org/10.21037/cdt.2017.03.03 PMID: 28529919

[180] Xiao, Y.; Su, X.; Huang, W.; Zhang, J.; Peng, C.; Huang, H.; Wu, X.; Huang, H.; Xia, M.; Ling, W. Role of S-adenosylhomocysteine in cardiovascular disease and its potential epigenetic mechanism. Int. J. Biochem. Cell Biol., 2015, 67, 158-166. http://dx.doi.org/10.1016/j.biocel.2015.06.015 PMID: 26117455

[181] Gao, J.; Cahill, C.M.; Huang, X.; Roffman, J.L.; Lamon-Fava, S.; Fava, M.; Mischoulon, D.; Rogers, J.T. S-Adenosyl Methionine and Transmethylation Pathways in Neuropsychiatric Diseases Throughout Life. Neurotherapeutics, 2018, 15(1), 156-175. http://dx.doi.org/10.1007/s13311-017-0593-0 PMID: 29340929

[182] Sharma, A.; Gerbarg, P.; Bottiglieri, T.; Massoumi, L.; Carpenter, L.L.; Lavretsky, H.; Muskin, P.R.; Brown, R.P.; Mischoulon, D. as Work Group of the American Psychiatric Association Council on Research. S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research. J. Clin. Psychiatry, 2017, 78(6), e656-e667. http://dx.doi.org/10.4088/JCP.16sr11113 PMID: 28682528

[183] Thompson, M.A.; Bauer, B.A.; Loehrler, L.L.; Cha, S.S.; Mandrekar, J.N.; Sood, A.; Wahner-Roedler, D.L. Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trial. J. Altern. Complement. Med., 2009, 15(5), 523-529. http://dx.doi.org/10.1089/acm.2008.0402 PMID: 19422296

[184] Mischoulon, D.; Price, L.H.; Carpenter, L.L.; Tyrka, A.R.; Papakostas, G.I.; Baer, L.; Dording, C.M.; Clan, A.J.; Durham, K.; Walker, R.; Ludington, E.; Fava, M. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J. Clin. Psychiatry, 2014, 75(4), 370-376. http://dx.doi.org/10.4088/JCP.13m08591 PMID: 24500245

[185] Sarris, J; Price, L; Carpenter, L; Tyrka, A; Ng, C; Papakostas, G S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re analysis of Data from a Randomized Clinical Trial. Pharmacoepidemiol Drug Saf., 2015, 48(04/05), 141-144. http://dx.doi.org/10.1002/pds.4120 PMID: 25166485

[186] Trevino, K.; McClintock, S.M.; McDonald Fischer, N.; Vora, A.; Husain, M.M. Defining treatment-resistant depression: a comprehensive review of the literature. Ann. Clin. Psychiatry, 2014, 26(3), 222-232. PMID: 25166485

[187] McIntyre, R.S.; Fillieux, M-J.; Martinez, L.; Patry, S.; Carvalho, A.; Cha, D.S.; Barakat, M.; Miguez, M. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J. Affect. Disord., 2014, 156, 1-7. http://dx.doi.org/10.1016/j.jad.2013.10.043 PMID: 24314926